- 19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries
- Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine
- Out-licenses its patented technology to third party partners, with several deals signed or pending
When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way: bioavailability matters. The company realized that if hemp oil ingredients were infused within lipids found in popular foods, the common problems of bad taste, poor absorption in the body and lack of product variety could be solved.
Lexaria has since developed a superior method of lipid-delivery technology through a patented process that does this by infusing the beneficial elements of hemp oil to lipid molecules. Lexaria reminds consumers that it is not mixing hemp oil into a product; it is infusing organically sourced, high purity hemp oil inside the molecules of other ingredients to produce superior tasting and performing food and beverages, including premium teas, protein energy bars and hemp oil capsules formulated with ginseng and ginkgo for enhanced memory and focus.
Additionally, this technologically superior method of delivery is being considered for other products in demand by consumers, namely nicotine-based products. Lexaria’s method could remove many of the dangerous side effects of nicotine, although the patented molecular delivery technology for this product remains in its early stages (http://nnw.fm/HZov0).
Lexaria is also seeking patents to use its lipophilic enhancement technology for tetrahydrocannabinol (THC) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), nicotine and other molecules. New business-to-business relationships are on the horizon in the fields of vitamins, NSAIDs and nicotine delivery.
For more information, visit the company’s website www.LexariaEnergy.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
